Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 265

1.

Capturing cancer initiating events in OncoCL, a cancer cell ontology.

Dolan ME.

AMIA Jt Summits Transl Sci Proc. 2014 Apr 7;2014:41. eCollection 2014.

2.

Association of an inherited genetic variant with vincristine-related peripheral neuropathy in children with acute lymphoblastic leukemia.

Diouf B, Crews KR, Lew G, Pei D, Cheng C, Bao J, Zheng JJ, Yang W, Fan Y, Wheeler HE, Wing C, Delaney SM, Komatsu M, Paugh SW, McCorkle JR, Lu X, Winick NJ, Carroll WL, Loh ML, Hunger SP, Devidas M, Pui CH, Dolan ME, Relling MV, Evans WE.

JAMA. 2015 Feb 24;313(8):815-23. doi: 10.1001/jama.2015.0894.

PMID:
25710658
3.

Modeling chemotherapeutic neurotoxicity with human induced pluripotent stem cell-derived neuronal cells.

Wheeler HE, Wing C, Delaney SM, Komatsu M, Dolan ME.

PLoS One. 2015 Feb 17;10(2):e0118020. doi: 10.1371/journal.pone.0118020. eCollection 2015.

4.

Methodology for the inference of gene function from phenotype data.

Ascensao JA, Dolan ME, Hill DP, Blake JA.

BMC Bioinformatics. 2014 Dec 12;15(1):405. [Epub ahead of print]

5.

Pharmacokinetics and pharmacogenomics of daunorubicin in children: a report from the Children's Oncology Group.

Thompson P, Wheeler HE, Delaney SM, Lorier R, Broeckel U, Devidas M, Reaman GH, Scorsone K, Sung L, Dolan ME, Berg SL.

Cancer Chemother Pharmacol. 2014 Oct;74(4):831-8. doi: 10.1007/s00280-014-2535-4. Epub 2014 Aug 14.

6.

Identification and validation of genetic variants that influence transcription factor and cell signaling protein levels.

Hause RJ, Stark AL, Antao NN, Gorsic LK, Chung SH, Brown CD, Wong SS, Gill DF, Myers JL, To LA, White KP, Dolan ME, Jones RB.

Am J Hum Genet. 2014 Aug 7;95(2):194-208. doi: 10.1016/j.ajhg.2014.07.005. Epub 2014 Jul 31.

7.

Linking the genetic architecture of cytosine modifications with human complex traits.

Zhang X, Moen EL, Liu C, Mu W, Gamazon ER, Delaney SM, Wing C, Godley LA, Dolan ME, Zhang W.

Hum Mol Genet. 2014 Nov 15;23(22):5893-905. doi: 10.1093/hmg/ddu313. Epub 2014 Jun 18.

PMID:
24943591
8.

Poly-omic prediction of complex traits: OmicKriging.

Wheeler HE, Aquino-Michaels K, Gamazon ER, Trubetskoy VV, Dolan ME, Huang RS, Cox NJ, Im HK.

Genet Epidemiol. 2014 Jul;38(5):402-15. doi: 10.1002/gepi.21808. Epub 2014 May 2.

PMID:
24799323
9.

Protein quantitative trait loci identify novel candidates modulating cellular response to chemotherapy.

Stark AL, Hause RJ Jr, Gorsic LK, Antao NN, Wong SS, Chung SH, Gill DF, Im HK, Myers JL, White KP, Jones RB, Dolan ME.

PLoS Genet. 2014 Apr 3;10(4):e1004192. doi: 10.1371/journal.pgen.1004192. eCollection 2014 Apr.

10.

Chemotherapy-induced peripheral neurotoxicity and ototoxicity: new paradigms for translational genomics.

Travis LB, Fossa SD, Sesso HD, Frisina RD, Herrmann DN, Beard CJ, Feldman DR, Pagliaro LC, Miller RC, Vaughn DJ, Einhorn LH, Cox NJ, Dolan ME; Platinum Study Group.

J Natl Cancer Inst. 2014 Mar 12;106(5). pii: dju044. doi: 10.1093/jnci/dju044. Review.

11.

Identification of genetic variants associated with capecitabine-induced hand-foot syndrome through integration of patient and cell line genomic analyses.

Wheeler HE, González-Neira A, Pita G, de la Torre-Montero JC, Alonso R, Lopez-Fernandez LA, Alba E, Martín M, Dolan ME.

Pharmacogenet Genomics. 2014 May;24(5):231-7. doi: 10.1097/FPC.0000000000000037.

PMID:
24595012
12.

The role of gene body cytosine modifications in MGMT expression and sensitivity to temozolomide.

Moen EL, Stark AL, Zhang W, Dolan ME, Godley LA.

Mol Cancer Ther. 2014 May;13(5):1334-44. doi: 10.1158/1535-7163.MCT-13-0924. Epub 2014 Feb 25.

PMID:
24568970
13.

Integrating cell-based and clinical genome-wide studies to identify genetic variants contributing to treatment failure in neuroblastoma patients.

Pinto N, Gamazon ER, Antao N, Myers J, Stark AL, Konkashbaev A, Im HK, Diskin SJ, London WB, Ludeman SM, Maris JM, Cox NJ, Cohn SL, Dolan ME.

Clin Pharmacol Ther. 2014 Jun;95(6):644-52. doi: 10.1038/clpt.2014.37. Epub 2014 Feb 18.

PMID:
24549002
14.

EPS8 inhibition increases cisplatin sensitivity in lung cancer cells.

Gorsic LK, Stark AL, Wheeler HE, Wong SS, Im HK, Dolan ME.

PLoS One. 2013 Dec 19;8(12):e82220. doi: 10.1371/journal.pone.0082220. eCollection 2013.

15.

RRM1 and RRM2 pharmacogenetics: association with phenotypes in HapMap cell lines and acute myeloid leukemia patients.

Cao X, Mitra AK, Pounds S, Crews KR, Gandhi V, Plunkett W, Dolan ME, Hartford C, Raimondi S, Campana D, Downing J, Rubnitz JE, Ribeiro RC, Lamba JK.

Pharmacogenomics. 2013 Sep;14(12):1449-66. doi: 10.2217/pgs.13.131.

16.

Institutional Profile: University of Chicago Center for Personalized Therapeutics: research, education and implementation science.

Dolan ME, Maitland ML, O'Donnell PH, Nakamura Y, Cox NJ, Ratain MJ.

Pharmacogenomics. 2013 Sep;14(12):1383-7. doi: 10.2217/pgs.13.134.

17.

Cell cycle arrest in a model of colistin nephrotoxicity.

Eadon MT, Hack BK, Alexander JJ, Xu C, Dolan ME, Cunningham PN.

Physiol Genomics. 2013 Oct 1;45(19):877-88. doi: 10.1152/physiolgenomics.00076.2013. Epub 2013 Aug 6.

18.

Genome-wide variation of cytosine modifications between European and African populations and the implications for complex traits.

Moen EL, Zhang X, Mu W, Delaney SM, Wing C, McQuade J, Myers J, Godley LA, Dolan ME, Zhang W.

Genetics. 2013 Aug;194(4):987-96. doi: 10.1534/genetics.113.151381. Epub 2013 Jun 21.

19.

Genetic and epigenetic variants contributing to clofarabine cytotoxicity.

Eadon MT, Wheeler HE, Stark AL, Zhang X, Moen EL, Delaney SM, Im HK, Cunningham PN, Zhang W, Dolan ME.

Hum Mol Genet. 2013 Oct 1;22(19):4007-20. doi: 10.1093/hmg/ddt240. Epub 2013 May 29.

20.

Lymphoblastoid cell lines in pharmacogenomics: how applicable are they to clinical outcomes?

Stark AL, Dolan ME.

Pharmacogenomics. 2013 Apr;14(5):447-50. doi: 10.2217/pgs.13.32. No abstract available.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk